24-May-2023 | D | Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, May 24, 2023 at 04.00 p.m. has inter-alia, considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 2023 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. Enclosed are: a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Recommended Final Dividend at 7% per Equity Share having Face Value of Rs. 10/- each for the Financial Year 2022-23 subject to the approval of the Shareholders at the ensuing 36T Annual General Meeting of the Company;
| 22-Sep-2023 | |
29-Jun-2021 | D | The Board of Directors of the Company at its meeting today i.e. 28th June, 2021 has recommended Dividend of Rs. 0.7/- per share of Rs. 10 each (7 %) for the financial year ended 31st March, 2021 subject to approval of the Shareholders at the ensuing Annual General Meeting of the Company. | 16-Sep-2021 | |
11-Jun-2019 | D | The Board in its meeting had considered and approved the Dividend of Rs. 0.60/- per Rs.10/- Equity Share of the Company.
We would like to inform you that the 32nd Annual General Meeting ('AGM') of the Company is scheduled to be held on Tuesday, September 24, 2019 at 09:00 A.M. at Ramee Guest Line Hotel - Dadar Plot No. 3, Kohinoor Road, Dadar, Mumbai - 400 014.
The cut-off date for entitlement to Dividend as declared by the Company at the rate of 6.5% shall be Tuesday, September 17, 2019.
(As Per BSE Announcement Dated on 22/07/2019) | 16-Sep-2019 | |
19-Jun-2018 | D | Fredun Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 18, 2018, inter alia, have considered and approved the following:
- Recommended Final Dividend @ 6% i.e., Rs. 0.60/- per Equity Share having face value of Rs. 10/- each for the Financial Year 2017-18; subject to the Approval of the Shareholders at the ensuing Annual General Meeting of the Company. | 18-Sep-2018 | |
30-May-2017 | D | Fredun Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2017, inter alia, has transacted the following:
- Final Dividend at the rate of 6% to Equity Shareholders was approved by the Board and decided to be proposed for Shareholders approval at the upcoming Annual General Meeting. | 20-Sep-2017 | |
02-Apr-2016 | D | Fredun Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 31, 2016, have decided to presently cancel the matter of issuing the Equity shares of the Company to the Investors under the Preferential Guidelines.
Further, The Board of Directors of the Company at their meeting held on March 31, 2016 have declared an Interim Dividend of 0.60 paise (6%) per share for the year ending March 31, 2016. | 11-Apr-2016 | |
24-Apr-2024 | BC | Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2024 inter alia to consider and approve Notice is hereby given pursuant to R | 07-May-2024 | |
15-Apr-2024 | BC | Allotment of 20,000 Equity Shares to Non-Promoter upon conversion of Warrants into Equity Shares | 15-Apr-2024 | |
22-Mar-2024 | BC | This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotmen | 22-Mar-2024 | |
13-Mar-2024 | BC | Trading members of the Exchange are hereby informed that the under mentioned new securities of Fredun Pharmaceuticals Limited (Scrip Code - 539730) are listed and permitted to trade on the Exchange w | 14-Mar-2024 | |
05-Feb-2024 | BC | Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve To discuss consider and approve Una | 14-Feb-2024 | |
Announcement Date24-May-2023
Ex Dividend Date22-Sep-2023
Dividend(%)7
Announcement Date29-Jun-2021
Ex Dividend Date16-Sep-2021
Dividend(%)7
Announcement Date11-Jun-2019
Ex Dividend Date16-Sep-2019
Dividend(%)6
Announcement Date19-Jun-2018
Ex Dividend Date18-Sep-2018
Dividend(%)6
Announcement Date30-May-2017
Ex Dividend Date20-Sep-2017
Dividend(%)6
Announcement Date02-Apr-2016
Ex Dividend Date11-Apr-2016
Dividend(%)6
No Bonus has been declared by Fredun_Pharma
No Split has been declared by Fredun_Pharma
RightsNo Rights has been declared by Fredun_Pharma
Book Closure
07-May-2024 | - | Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2024 inter alia to consider and approve Notice is hereby given pursuant to R |
15-Apr-2024 | - | Allotment of 20,000 Equity Shares to Non-Promoter upon conversion of Warrants into Equity Shares |
22-Mar-2024 | - | This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotmen |
14-Mar-2024 | - | Trading members of the Exchange are hereby informed that the under mentioned new securities of Fredun Pharmaceuticals Limited (Scrip Code - 539730) are listed and permitted to trade on the Exchange w |
14-Feb-2024 | - | Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve To discuss consider and approve Una |